Child's A to C Cirrhosis Clinical Trial
Official title:
A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Hepatocellular Carcinoma
In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC
| Status | Recruiting |
| Enrollment | 300 |
| Est. completion date | December 31, 2024 |
| Est. primary completion date | December 31, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Clinical diagnosis of HCC - Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery 1. For TACE cohort, patients undergoing first cycle TACE are eligible. 2. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible. 3. For surgery cohort, patient undergoing surgery are eligible. - Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed - Child's A to Child's C liver function Exclusion Criteria: - ECOG performance status > 2 - Poorly controlled ascites |
| Country | Name | City | State |
|---|---|---|---|
| Hong Kong | Department of Clinical Oncology, Prince of Wales Hospital | Hong Kong |
| Lead Sponsor | Collaborator |
|---|---|
| Chinese University of Hong Kong |
Hong Kong,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall survival | 3 years | ||
| Secondary | Rate and grade of treatment complications | 2 years | ||
| Secondary | Liver stiffness (kPa) | 2 years |